BioDuro and Cenra API Solutions forge global API manufacturing joint venture in Taiwan
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027
The first of four planned modules at the new plant is expected to come online by summer 2026
The facility is expected to become operational by FY2028-29
One of India’s top integrated contract research, development, and manufacturing organizations (CRDMOs) is on a hiring spree
This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
Subscribe To Our Newsletter & Stay Updated